Vitamin D Supplementation in People With Epilepsy: A Systematic Review of Effects on Vitamin D Status, Bone Health, and Seizure Outcomes
Acta Neurologica Scandinavica · 2026-01 · 2026 (1)
DOI: 10.1155/ane/4570326 ↗Abstract
Background Vitamin D deficiency is highly prevalent among people with epilepsy (PWE) and may result from antiseizure medications (ASMs), lifestyle factors, and disease‐related mechanisms. Beyond skeletal effects, vitamin D exerts neurosteroid and immunomodulatory actions that may influence seizure susceptibility. Objective To systematically evaluate the effects of vitamin D supplementation in PWE on vitamin D status, bone health, seizure frequency, and other clinical outcomes; and to describe baseline vitamin D status and the role of ASMs in the populations studied. Methods PubMed/MEDLINE, Scopus, and ClinicalTrials.gov were searched from inception to August 31, 2026, in accordance with PRISMA 2020 and PRISMA‐S. Two reviewers independently screened records, extracted data, and assessed risk of bias with RoB 2, ROBINS‐I, or the Newcastle–Ottawa Scale, according to study design. Because of clinical and methodological heterogeneity, findings were synthesized narratively without meta‐analysis. Results Of 976 unique records screened, 24 reports of 21 studies published between 1973 and 2026 were included (eight randomized controlled trials, eight nonrandomized interventional studies, and 5 observational studies). Low 25‐hydroxyvitamin D [25(OH)D] was common at baseline; for example, 80% of adults in a Lebanese trial were deficient or insufficient, and 85% of patients enrolled in a French trial in drug‐resistant epilepsy had 25(OH)D below 30 ng/mL. Higher doses raised 25(OH)D more than lower doses or no treatment in every trial that compared them, but maintenance doses of 400–1000 IU/day often left concentrations below target. Bone mineral content or density increased in some trials of patients taking enzyme‐inducing ASMs, but dose comparisons showed no consistent between‐group difference in bone mineral density (BMD). In the two placebo‐controlled trials in drug‐resistant epilepsy ( n = 74 and n = 200), seizure frequency did not differ significantly between vitamin D and placebo; the improvements reported came from open‐label phases and uncontrolled comparisons. No included study was at low risk of bias. Seven of the eight randomized trials had some concerns and one was at high risk; the eight nonrandomized interventional studies were at serious ( n = 7) or critical ( n = 1) risk, and three of the five observational studies were of poor quality. Conclusions Vitamin D monitoring and repletion should be integrated into routine epilepsy care for skeletal protection. Current randomized evidence does not show an independent antiseizure effect, and adequately powered trials with standardized endpoints are needed.
EUVIMED